{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:39:26Z","timestamp":1777937966654,"version":"3.51.4"},"reference-count":30,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T00:00:00Z","timestamp":1734393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Merck","award":["(CrossRef Funder ID: 10.13039\/100009945)"],"award-info":[{"award-number":["(CrossRef Funder ID: 10.13039\/100009945)"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Mult Scler"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>CLASSIC-MS explored long-term outcomes of patients treated with cladribine tablets.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Assess long-term efficacy in patients previously enrolled in ORACLE-MS, a Phase III parent trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>ORACLE-MS included patients with a first clinical demyelinating event (FCDE or clinically isolated syndrome) who received \u2a7e1 course of cladribine tablets or placebo. With a median follow-up time of 9.5 years, CLASSIC-MS assessed conversion rates to clinically definite multiple sclerosis (CDMS), time-to-conversion, relapse rates, long-term mobility\/disability status and subsequent disease-modifying therapy (DMT) use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Of 227 patients from the ORACLE-MS cohort of 616, 68.7% were exposed to cladribine tablets and 31.3% were never exposed. Of the exposed patients at risk, 51.5% converted to CDMS with a median conversion time of 8.4 (95% confidence interval (CI): 5.4\u2013not estimable) years, versus 80.6%, median time 0.8 (95% CI: 0.3\u20132.4) years, for never exposed. Exposed patients were less likely to be using a wheelchair or ambulatory device or receive subsequent DMTs, and 53.2% were relapse-free versus 28.2% never exposed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Proportionally, more FCDE patients exposed to cladribine tablets experienced delayed conversion to CDMS and fewer relapses and were less likely to use a wheelchair or ambulatory device than never-exposed patients, at 9.5 years (median).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/13524585241302170","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T02:38:49Z","timestamp":1734489529000},"page":"44-58","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Long-term follow-up of patients with a first clinical demyelinating event (clinically isolated syndrome) who received cladribine tablets in CLASSIC-MS: Findings for the ORACLE-MS cohort"],"prefix":"10.1177","volume":"31","author":[{"given":"Gavin","family":"Giovannoni","sequence":"first","affiliation":[{"name":"Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexey","family":"Boyko","sequence":"additional","affiliation":[{"name":"Department of Neurology, Pirogov Russian National Research Medical University, Neurosurgery and Medical Genetics, Federal Center of Brain Research and Neurotechnologies, Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Correale","sequence":"additional","affiliation":[{"name":"Department of Neurology, FLENI Institute, Buenos Aires, Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Edan","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital of Rennes, Rennes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark S","family":"Freedman","sequence":"additional","affiliation":[{"name":"Department of Medicine and the Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Montalban","sequence":"additional","affiliation":[{"name":"Department of Neurology, Centre d\u2019Esclerosi M\u00faltiple de Catalunya (Cemcat), Hospital Universitario Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kottil","family":"Rammohan","sequence":"additional","affiliation":[{"name":"University of Miami School of Medicine, MS Research Center, Miami, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dusan","family":"Stefoski","sequence":"additional","affiliation":[{"name":"Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bassem","family":"Yamout","sequence":"additional","affiliation":[{"name":"Neurology Institute, Harley Street Medical Center, Abu Dhabi, UAE; American University of Beirut Medical Center, Beirut, Lebanon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Leist","sequence":"additional","affiliation":[{"name":"Division of Clinical Neuroimmunology, Jefferson University, Comprehensive MS Center, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aida","family":"Aydemir","sequence":"additional","affiliation":[{"name":"EMD Serono Research & Development Institute, Inc., an affiliate of Merck KGaA, Billerica, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laszlo","family":"Borsi","sequence":"additional","affiliation":[{"name":"Merck Healthcare KGaA, Darmstadt, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Verdun di Cantogno","sequence":"additional","affiliation":[{"name":"EMD Serono Research & Development Institute, Inc., an affiliate of Merck KGaA, Billerica, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,12,17]]},"reference":[{"key":"bibr1-13524585241302170","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13819"},{"key":"bibr2-13524585241302170","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70005-5"},{"key":"bibr3-13524585241302170","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102695"},{"key":"bibr4-13524585241302170","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-018-09169-w"},{"key":"bibr5-13524585241302170","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200009283431301"},{"key":"bibr6-13524585241302170","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)17271-1"},{"key":"bibr7-13524585241302170","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61259-9"},{"key":"bibr8-13524585241302170","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70262-9"},{"key":"bibr9-13524585241302170","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70191-7"},{"key":"bibr10-13524585241302170","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.4905"},{"key":"bibr11-13524585241302170","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000636"},{"key":"bibr12-13524585241302170","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.33.11.1444"},{"key":"bibr13-13524585241302170","doi-asserted-by":"publisher","DOI":"10.1177\/1352458518790397"},{"key":"bibr14-13524585241302170","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102519"},{"key":"bibr15-13524585241302170","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-009-5441-7"},{"key":"bibr16-13524585241302170","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0902533"},{"key":"bibr17-13524585241302170","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517727603"},{"key":"bibr18-13524585241302170","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231161494"},{"key":"bibr19-13524585241302170","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30470-2"},{"key":"bibr20-13524585241302170","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-018-8764-4"},{"key":"bibr21-13524585241302170","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac016"},{"key":"bibr22-13524585241302170","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517751049"},{"key":"bibr23-13524585241302170","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-018-8752-8"},{"key":"bibr24-13524585241302170","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200048"},{"key":"bibr25-13524585241302170","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2013.03.018"},{"key":"bibr26-13524585241302170","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2022.577966"},{"key":"bibr27-13524585241302170","doi-asserted-by":"publisher","DOI":"10.7224\/1537-2073.2013-041"},{"key":"bibr28-13524585241302170","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14823"},{"key":"bibr29-13524585241302170","unstructured":"Multiple Sclerosis International Federation. Global MS employment report, 2016, https:\/\/www.msif.org\/wp-content\/uploads\/2016\/05\/Global-MS-Employment-Report-2016.pdf (accessed 5 October 2022)."},{"key":"bibr30-13524585241302170","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102487"}],"container-title":["Multiple Sclerosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585241302170","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13524585241302170","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585241302170","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:16:56Z","timestamp":1777695416000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13524585241302170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,17]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1177\/13524585241302170"],"URL":"https:\/\/doi.org\/10.1177\/13524585241302170","relation":{},"ISSN":["1352-4585","1477-0970"],"issn-type":[{"value":"1352-4585","type":"print"},{"value":"1477-0970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,17]]}}}